Background and aims Edoxaban proved to be safe and effective also in fragile patients, but
its administration through percutaneous endoscopic gastrostomy (PEG) has not been …

Background Extensive data support the superior safety without any trade-off in efficacy of
direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKA) in patients with …

Extensive data support the safety of direct oral anticoagulants compared with vitamin K
antagonists in patients with non‐valvular atrial fibrillation, leading to a significantly increase …

Aims The ORal anticoagulants In fraGile patients with percutAneous endoscopic
gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of …

In clinical practice, edoxaban is sometimes prescribed for off-label use based on the
hypothesis that it is as safe and effective as warfarin. However, there is limited safety …

Aim As the direct oral anticoagulant most recently approved in China, data pertaining to
clinical edoxaban use are still scarce. This study investigated the prevalence of and …

Aims: This study investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of
once-daily postprandial doses of edoxaban 60 mg in healthy Chinese subjects. Methods: 6 …

What is known and objective Edoxaban has three dose adjustment factors (creatinine
clearance, 15‐50 mL/min; body weight, 60 kg or less; and concomitant medication with …

Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous
thromboembolism treatment or stroke prevention in atrial fibrillation. Effectiveness and safety …

Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention
and treatment of venous thromboembolism (VTE) and for the prevention of stroke in atrial …